Scarica l'app Stockscreener
10.60
2.75%
-0.30
Dopo l'orario di chiusura:
10.53
-0.07
-0.66%
Precedente Chiudi:
$10.90
Aprire:
$10.74
Volume 24 ore:
540.07K
Relative Volume:
4.52
Capitalizzazione di mercato:
$175.30M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-3.4754
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
+6.11%
1M Prestazione:
+25.30%
6M Prestazione:
+11.34%
1 anno Prestazione:
-46.36%
Intervallo 1D:
$10.22
$11.14
Intervallo di 1 settimana:
$8.75
$11.14
Portata 52W:
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Confronta RAPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
10.60 | 180.26M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Downgrade | Stifel | Buy → Hold |
| 2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-22 | Downgrade | UBS | Buy → Neutral |
| 2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Iniziato | Evercore ISI | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-09-14 | Iniziato | Berenberg | Buy |
| 2023-08-09 | Iniziato | Stifel | Buy |
| 2023-06-15 | Iniziato | Barclays | Overweight |
| 2023-01-04 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | CapitalOne | Overweight |
| 2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Iniziato | JP Morgan | Overweight |
| 2021-08-12 | Iniziato | SVB Leerink | Outperform |
| 2021-06-21 | Iniziato | Piper Sandler | Overweight |
| 2020-06-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Iniziato | ROTH Capital | Buy |
| 2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-25 | Iniziato | UBS | Buy |
| 2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
What high frequency data says about RAPT Therapeutics Inc.July 2025 Reactions & Momentum Based Trading Ideas - Newser
Has RAPT Therapeutics Inc. formed a bullish divergenceJuly 2025 Sector Moves & Daily Volume Surge Signals - Newser
Sentiment analysis tools applied to RAPT Therapeutics Inc.Free Profit Target Stock Opportunity Monitor - Newser
Understanding RAPT Therapeutics Inc.’s price movementForecasting Stock Moves with AI Insights - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionLow Cost High Gain Picks - newsyoung.net
RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8. - AInvest
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Will RAPT Therapeutics Inc. continue its uptrendSector Rotation and Stock Opportunity Analysis - Newser
Volume spikes in RAPT Therapeutics Inc. stock – what they meanFree Smart Trade Plans With Risk Protection - Newser
Analyzing drawdowns of RAPT Therapeutics Inc. with statistical toolsAlgorithmic Forecast for Swing Trading Picks - Newser
Building trade automation scripts for RAPT Therapeutics Inc.Intelligent Trade Forecast With AI Analytics - Newser
Historical volatility pattern of RAPT Therapeutics Inc. visualizedRisk Aware Trading Ideas with Alert Levels - Newser
Ranking RAPT Therapeutics Inc. among high performing stocks via toolsSmart Swing Picks with Confirmed Signals - Newser
How to forecast RAPT Therapeutics Inc. trends using time seriesPredictable Entry Strategy With Technical Backing - Newser
Multi asset correlation models including RAPT Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Applying Elliott Wave Theory to RAPT Therapeutics Inc.Buy and Hold Position Summary Review - Newser
Published on: 2025-08-09 04:24:12 - beatles.ru
Using AI based signals to follow RAPT Therapeutics Inc.Stock Entry Point Planner with Volume Spike - Newser
Using Ichimoku Cloud for RAPT Therapeutics Inc. technicalsAlpha Stock Picks with Chart Confirmation - Newser
RAPT Therapeutics Inc. stock daily chart insightsTrade Setup Builder with Custom Alerts - Newser
RAPT Therapeutics Reports Q2 2025 Financial Results: Net Loss of $34.8 Million, Cash and Securities Valued at $169 Million. - AInvest
Full technical analysis of RAPT Therapeutics Inc. stockAlpha Trade Flow With Risk Calibration - Newser
Wells Fargo lowers Rapt Therapeutics stock price target to $38 on model changes - Investing.com Canada
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛
Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges - TipRanks
RAPT Therapeutics Reports Q2 2025 Financial Results - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapt Therapeutics reports Q2 EPS (65c), consensus (65c) - TipRanks
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Q2 net loss narrows to $17.6 mln, R&D expenses drop - MarketScreener
RAPT Therapeutics Reports Second Quarter 2025 Financial Results - The Manila Times
RAPT Therapeutics Q2 revenue up 16% YoY to $7.5mln. - AInvest
RAPT Therapeutics Slashes Losses by $10M, Preps Major Food Allergy Trial Launch - Stock Titan
What machine learning models say about RAPT Therapeutics Inc.Real-Time Signal Tracking with Entry Level - Newser
Clear Street raises Rapt Therapeutics stock price target to $24 on RPT904 potential - Investing.com Canada
Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):